NovaBridge Biosciences (NBP) — Strategic Asset Allocation Index
NovaBridge Biosciences (NBP) has a Strategic Asset Allocation Index of 2.2% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $40.32 Million) total $40.32 Million, measured against net assets of $1.84 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See NovaBridge Biosciences balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
NovaBridge Biosciences Strategic Asset Allocation Index (2021–2024)
This chart shows how NovaBridge Biosciences's Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the index stands at 2.2%, representing strategic assets of $40.32 Million against net assets of $1.84 Billion USD. For live market cap and overall valuation, see market value of NovaBridge Biosciences.
Annual Strategic Asset Allocation Index for NovaBridge Biosciences (2021–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for NovaBridge Biosciences from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See NovaBridge Biosciences book value and equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 15.3% | $30.82 Million | $- | $30.82 Million | $201.16 Million | ▲ +15.3 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $1.72 Billion | ▼ -0.1 pp |
| 2022 | 0.1% | $4.47 Million | $- | $4.47 Million | $3.01 Billion | ▼ -1.1 pp |
| 2021 | 1.2% | $55.24 Million | $- | $55.24 Million | $4.59 Billion | — |